AnteoTech (ASX:ADO) - CEO, Derek Thomson
CEO, Derek Thomson
Source: AnteoTech
Market Herald logo


Be the first with the news that moves the market
  • AnteoTech (ADO) signs an agreement with Ramma Dental to exclusively distribute two of its products in Greece and Cyprus
  • Ramma Dental will distribute the EuGeni Reader platform and SARS-CoV-2 Antigen Rapid Diagnostic Test (RDT) which are designed to detect COVID-19
  • AnteoTech now has distribution deals in place for EuGeni in 12 countries such as the UK, Australia, Turkey, New Zealand, Southeast Asia and the Philippines
  • The agreement has an initial three year term, with potential to extend, and ADO is in advanced discussions regarding further distribution agreements
  • Company shares are up 9.52 per cent to trade at 23 cents

AnteoTech (ADO) has signed a distribution agreement with Ramma Dental for its EuGeni Reader platform and SARS-CoV-2 Antigen Rapid Diagnostic Test (RDT).

Ramma Dental is a well-established distributor in Greece and Cyprus who started off with selling dental products but has grown to supply a wide range of medical devices and has a strong network of customers.

From October 1, Ramma Dental will exclusively distribute the Eugeni Reader platform and SARS CoV-2 RDT, which together are designed to efficiently detect the presence of COVID-19 in humans.

AnteoTech CEO, Derek Thomson, commented on the latest deal.

“AnteoTech is aggressively growing the sales pipeline for the EuGeni reader by locking in distribution agreements that allow us to rapidly scale-up the platform’s
roll-out,” he said.

Over the last few months, the company has secured a number of distribution agreements and, including today’s, ADO has distribution deals in place for 12 countries.

Specific countries that will now distribute EuGeni include the UK, Australia, New Zealand, Thailand, Malaysia, Indonesia, Vietnam, Singapore, Myanmar, the Philippines, Turkey, Greece and Cyprus.

According to AnteoTech, it is in advanced discussions with several more distributors which means its products may be distributed in even more countries.

“This is a critical pillar in establishing a sustainable business over the longer-term, and ensures that the EuGeni platform is recognised as the preferred and most dependable rapid test in these markets,” Mr Thomson said.

AnteoTech is also completing regulatory requirements to register the EuGeni reader and test in some of the already secured countries as regulations are becoming more ‘rigorous’ in many jurisdictions.

The latest deal with Ramma Dental has a three-year term but may be extended by a further two years if both companies agree to this.

Company shares were up 9.52 per cent to trade at 23 cents at 1:24 pm AEST.

ADO by the numbers
More From The Market Herald
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.